New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Check below for free stories on BAYRY;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
05:57 EDTBAYRYBayer reports Q2 net income EU 953M vs. EU 841M last year
Subscribe for More Information
05:55 EDTBAYRYBayer says Stivargahas approved in Europe for GIST
Subscribe for More Information
July 25, 2014
07:32 EDTBAYRYAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
05:35 EDTBAYRYBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 24, 2014
13:06 EDTBAYRYBayer treatment for systemic sclerosis receives FDA orphan designation
Subscribe for More Information
07:12 EDTBAYRYEvogene announces amendment to Bayer wheat agreement
Subscribe for More Information
July 21, 2014
07:14 EDTBAYRYAmerican Association of Physicists in Medicine to hold annual meeting
56th Annual Meeting of AAPM to be held in Austin, Texas on July 20-25.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use